This paper is only available as a PDF. To read, Please Download here.
Abstract
A series of 40 patients with lobar pneumonia treated by artificial pneumothorax is
presented, with a mortality of 35 per cent. A control group of 100 patients with lobar
pneumonia treated by other methods is also presented, with a mortality of 51 per cent.
In addition to a decreased mortality, the chief benefits of artificial pneumothorax
are relief of pain, dyspnea, cyanosis, and “toxicity.” It also shortens the febrile
period sometimes by crisis, sometimes by lysis, and so lessens the number of hospital
days per patient. Artificial pneumothorax is of little aid in the treatment of well-established
pneumococcemias; it will not abort toxic psychoses, and it apparently has little influence
on the prevention of the more severe complications of lobar pneumonia.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Translational ResearchAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Artificial Pneumothorax in the Treatment of Lobar Pneumonia.J. A. M. A. 1934; 102: 1907
Lilienthal, H.: Personal communication.
Article info
Publication history
Received:
October 3,
1934
Identification
Copyright
© 1935 Published by Elsevier Inc.
